There’s a new kind of nosy parker on the rise in the United States, a person who thinks it’s fine to blurt out “Are you on ...

Older adults with diabetes using GLP-1 receptor agonist medications may face increased risk of serious eye conditions, study ...

Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

Novo Nordisk said on Friday the U.S. Food and Drug Administration had granted accelerated approval for its weight-loss drug ...

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

Doctors and many patients say GLP-1 drugs can help solve the growing problem of obesity. But some bristle at the thought that ...

The cost of Mounjaro, a popular weight-loss injection, is set to rise sharply in the UK – from £122 to £330 – a 170 per cent increase starting this September. The price hike, confirmed by US ...

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...

It’s no secret that obesity is becoming an epidemic in the United  States. It’s estimated that by 2030, 50 percent of ...